Johnson & Johnson's Spravato, a ketamine-derived nasal spray, is offering new hope for patients with treatment-resistant depression. Unlike traditional antidepressants that can take weeks to work, Spravato acts rapidly, often within hours, to alleviate symptoms. It is approved for use in conjunction with an oral antidepressant for adults who have not responded to other treatments.
Spravato works differently from standard depression medications by targeting NMDA receptors in the brain, boosting glutamate activity. This novel mechanism helps create new neural connections, potentially reversing the negative effects of chronic stress on brain function.
Despite its promise, Spravato is not a first-line treatment due to its potential for side effects and abuse. It is administered under medical supervision in a healthcare setting, where patients are monitored for at least two hours after each dose. Common side effects include dissociation, dizziness, and sedation.
As mental health awareness grows, Spravato represents a significant advancement for the millions who have not benefited from existing therapies. However, experts caution that more research is needed to understand long-term effects and optimal patient selection.